HİPOFİZ ADENOMLARINDA RADYOTERAPİ

DEMİRBAŞ, Berrin ÇARMIKLI; Gürsoy, Gül

HİPOFİZ ADENOMLARINDA RADYOTERAPİ

Gül GÜRSOY, (Ankara Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Ankara Türkiye)

Berrin ÇARMIKLI DEMİRBAŞ (TOBB Ekonomi ve Teknoloji Üniversitesi Hastanesi, Endokrinoloji ve Metaboizma Hastalıkları Kliniği, Ankara Türkiye)

Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi

9 0

Yıl: 2019 Cilt: 52 Sayı: 2 Sayfa Aralığı: 174 - 180 Metin Dili: Türkçe İndeks Tarihi: 05-11-2020

HİPOFİZ ADENOMLARINDA RADYOTERAPİ

Öz:

Cerrahi teknik ve medikal tedavilerdeki gelişmelere rağmen önemlibir sayıda hipofiz adenomu endokrinojik olarak aktif kalabilir,radyolojik olarak persistan hastalık sergileyebilir veya nüksedebilir.Radyoterapi bu ısrarcı adenom tiplerinde gün geçtikçe daha önemlibir tedavi modalitesi olmaktadır. Bu tedavi şekli ile endokrinolojikremisyon oranları değişken olmakla birlikte iyidir ve radyolojiktümör kontrol oranları yüksektir. Radyoterapi sonrası tümörtipi ve boyutu, verilen radyoterapi şekli ile uyumlu olmak üzerehipopitüitarizm en yüksek oranda, daha az oranlarda nörolojik vevasküler komplikasyonlara rastlanmaktadır. Sonuç olarak diğertedavi şekillerine refrakter hipofiz tümörlerinde minimal envaziv,emin ve efektif bir opsiyon olarak radyoterapi akla getirilmelidir.

Anahtar Kelime:

RADIOTHERAPY FOR PITUITARY ADENOMAS

Öz:

Despite improvements in surgical technics and medical treatment a significant number of pituitary adenomas may remain endocrinologically active, may exhibit radiologically persistent disease or may recur. Day after day, radiotherapy in these persistent adenoma types, becomes an important treatment modality. Although with this type of treatment endocrinological remission rates are highly variable, they are good and radiological tumor control rates are high. After radiotherapy, depending on tumor type and size, radiothepay type, hipopituitarism at the highest rate, and less likely neurological and vascular complications are found. As a result, in hypophysis tumors refractory to other treatment modalities, radiotherapy must be kept in mind as a minimally invasive, safe and effective option.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1.)Deyneli O, Yazıcı D. Radiotherapy for pituitary adenomas. Turkiye Klinikleri J Int Med Sci. 2006; 2:71-6.
2.)Landolt AM, Haller D, Domax N et al, Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractioned radiotherapy. J Neurosurg. 1998; 88:1002-8.
3.)Sheehan JP, Pouratian N, Steiner L, Laws ER, Vance MI, Gama Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg. 2011;114: 303-9.
4.)Castinetti F, Nagai M, Dufour H, Kuhn JM, Morangel I, Jaquet P et al, Gama Knife surgery is a successful adjunctive treatment in Cushing’s disease. Eur J Endocrinol. 2007; 156: 91-8.
5.)Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C et al, Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery. A study of 142 patients. Eur J Endocrinol. 2010; 163: 193-200.
6.)Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell JB et al, Long term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg. 2008,108:736-45.
7.)Erridge SC, Conkey DS, Stockton D, Strachan MW, Statham PF, Whittle IR et al, Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol. 2009; 93:597-601.
8.)Loeffler JS, Shih HA, Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab. 2011;96:1992-2003.
9.)Zierhut D, Flentje M, Adolph J, Erdmann J, Raue F, Wannenmacher M, External radiotherapy of pituitary adenomas. Int J Radiat Oncol Biol Phys. 1995,33: 307-14.
10.)Colin P, Jovenin N, Delemer B, Caron J, Grule H, Hecart AC et al, Treatment of pituitary adenomas by fractioned stereotactic radiotherapy: a prospective study of 110 patients. Int J Radiat Oncol biol Phys. 2005;62: 333-41.
11.)Paek SH, Downes MB, Bednarz G, Keane WM, Werner-Wasik M, Curran WJ Jr et al, Integration of surgery with fractioned stereotactic radiotherapy of nonfunctional pituitary adenomas. Int J Radiat Oncol Biol Phys. 2005;61: 795-808.
12.)Ronson BB, Schulte RW, Han KP, Loredo LN, Slater JM, Slater JD, Fractioned proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys. 2006;64: 425-34.
13.)Sheehan JP, Nirajan A, Sheehan JM, Jane JA Jr, Laws ER, Kondziolka D et al, Stereotactic radisurgery for pituitary adenomas. An internmediate review of its safety,efficacy and role in the neurosurgical treatment armamentarium. J Neurosurg. 2005; 102:678-91.
14.)Mingione V, Yen CP, Vance ML, Steiner M, Sheehan J, Laws ER et al, Gama surgery in the treatment of nonsecretory pituitary macroadenoma. J Neurosurg. 2006; 104:876-83.
15.)Erfurth SM, Bulow B, Svahn-Japper G, Norrving B, Odh K, Mikoczy Z et al, Risk factors of cerebrovascular deaths in patients irradiated for pituitary tumors. J Clin Endocrinol Metab. 2002; 37:1002-9.
16.)Brada M, Ashley S, Ford D, Traish D, Buurchell L, Rajan B, Cerebrovascular mortality in patients with pituitary adenoma. J Clin Endocrinol(Oxford). 2002;57: 713-7.
17.)Jennings AS, Liddle GW, Orth DN, Results of treating childhood Cushing’s disease with pituitary irradiation. N Engl J Med. 1977; 297:957-62.
18.)Orth DN, Liddle GW, Results of treatment in 108 patients with Cushing’s syndrome. N Engl J Med. 1971; 285:242-7.
19.)Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S et al, The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med. 1977; 336:172-7.
20.)Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, Cantore G, Maurizi Enrici R, Long-term follow-up results of postoperative radiation therapy for Cushing’s disease. J Neurooncol. 2007;84:79-84.
21.)Sharpe GF, Kendall-Taylor P, Prescott RW, Ross WM, Davison C, Watson MJ et al, Pituitary function following megavoltage therapy for Cushing’s disease. Clin Endocrinol (Oxf). 1985; 22:169-77.
22.)Dias RP,Kumaran A, Chan LF, Martin L, Afshar F, Matson M et al, Diagnosis, management and therapeutic outcome in prepubertal Cushing’s disease. Eur J Endocrinol. 2010; 162:603-9.
23.)Kjelberg RN, Kliman B, Swisher B, Proton beam therapy of Cushing’s disease and Nelson’s syndrome.In: Black PML; ed. Secretory tumors of pituitary gland. 2nd edition. New York: Raven Pr; 1984. p 295-8.
24.)Cassar J, Doyke FH, Mashiter K, Joplin GF, Treatment of Cushing’s disease.in juveniles with interstitial pituitary irradiation. Clin Endocrinol (Oxf). 1979; 11:313-21.
25.)Höybye C, Grenback E, Rahn T, Degerblad M, Thoren M, Hulting AL, Adreno-corticotropic hormone producing pituitary tumors: 12 to 22 year follow up after treatment with stereotactic radiosurgery. Neurosurgery. 2001; 49: 284-91.
26.)Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML, Gama Knife surgery for Cushing’s disease. J Neurosurg. 2007;106: 980-7.
27.)Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF et al, Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Eng J Med. 1993;328:87-94.
28.)Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA, Conventional pituitary irradiation is effective in lowering serum growth hormone and insülin-like growth factor-1 in patients with acromegali. J Clin Endocrinol Metab. 2006; 91:1239-45.
29.)Thalassinos NC, Tsagarakis S, Ionnides G, Tzavara I, Papavasilliou C, Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegali: along-term follow-up study. Eur J Endocrinol. 1998; 138:160-3.
30.)Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R, Failure of radiotherapy in acromegali. Eur J Endocrinol. 2001;145: 717-26.
31.)Barrande G, Pittino-Lungo M, Coste J, Ponvent D, Bertagna X, Luton JP et al, Hormonal and metabolic effects of radiotherapy in acromegali: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab. 2000;85: 3779-83.
32.)Brada M, Ford D, Ashley S, Bliss JM, Crowley S, Mason M et al, Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma. BMJ. 1992; 304: 1343-6.
33.)Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC et al, ACTH deficiency, higher doses of hydrocortisone replacement and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab. 2009;94: 4216-23.
34.)Voges J, Kocher M, Runge M, Poggenborg J, Lehrke R, Lenartz D et al, Linear accelerator radiosurgery for pituitary macroadenomas. Cancer. 2006: 187:1355-64.
35.)Roberts BK, Ouyang DL, Lad SP, Chang SD, Harsh GR 4th, Adler JR Jr et al, Efficacy and safety of CyberKnife radiosurgery for acromegaly. Piyuitary. 2007;10: 19-25.
36.)Wattson DA, Tanguturi SK, Spiegel DY, Neimierko A, Biller BM, Nachtigall LB et al, Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys. 2014; 90: 532-9.
37.)Ronchi CL, Attanasio R, Verrua E, Cozzi R, Ferrante E, Loli P et al, Efficacy and tolerability of gama knife radiosurgery in acromegaly: a 10 year follow-up study. Clin Endocrinol (Oxf). 2009; 71:846-52.
38.)Petit JH, Biller BM, Coen JJ, Swearingen B, Ancukiewicz M, Bussiere M et al, Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract. 2007;13:726-34.
39.)Jezkova J, Marek J, Hana V, Krsek M, Weiss V, Vladyka V, Use of the Leksell gama knife in the treatment of prolactinoma patients. Clin Endocrinol (Oxf). 2009; 70:732-41.
40.)Wilson PJ, Williams JR, Smee RI, Single-centre experience of stereotactic radiosurgery and fractionated stereotactic radiotherapy forprolactinomas with the linear accelerator. J Med Imaging Radiat Oncol. 2015;59:371-8.
41.)Casaneuva FF, Molitch ME, Schlente JA, Abs R, Bonert V, Bronstein MD et al, Guidelines of the Pituitary Society fort he diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006; 65:265-73.
42.) Mayadaglı A, Dalkılıç Çalış M, İncekara O. Hipofiz Tümörlerinde External Radyoterapi Sonuçlarımız. SETB 2000; 34:46-8.
43.)Synder J, Fowble BF, Schatz NJ, Savino PJ, Gennarelli TA, Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med. 1986; 81: 457-62.
44.)Reiken S, Habermehl D, Welzel T, Mohr A, Lindel K, Debus J et al, Long term toxicity and prognostic factors of radiation therapy for secreting and non-secreting pituitary adenomas. Radiat Oncol. 2013; 8: 18-20.
45.)Mayo C, Martel MK, Marks LB, Flicker J, Nam J, Kirkpatrick J, Radiation dose- volüme effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys. 2010; 76: S28-35.
46.)Cifarelli CP, Schlesinger PC, Sheehan JP, Cranial nerve dysfunction following Gama Knife surgery for piyuitary adenomas: long term incidence and risk factors. J Neurosurg. 2012;116:1304-10.
47.)Boström JP, Meyer A, Pintea B, Gerlach R, Surber G, Lammering G et al, Risk-adapted single or fractionated stereotactic high-precision radiotherapy in a pooled series of nonfunctioning pituitary adenomas: high local control and low toxicity. Strahlenther Oncol. 2014;190:1095-103.
48.)Sattler Mg, Vroomen PC, Sluiter WJ, Schers HJ, van den Berg G, Langendijik JA et al, Incidence, causative mechanisms, and anatomic localization of stroke in pituitary adenoma patients treated with postoperative radiation therapy versus surgery alone. Int J Radiat Oncol Biol Phys. 2013; 87:53-9.
49.)Rim CH, Yang DS, Park JJ, Yoon WS, Lee JA, Kim CY, Radiotherapy for pituitary adenomas: long term outcome and complications. Radiation Oncol. 2011; 29:156-63.
50.)Grattan-Smith PJ, Morris JG, Langlands AO, Delayed radiation necrosis of the central nervous system in patients with pituitary tumors. J Neurol Neurosurg Psychiatry. 1992; 55:949-55.

APA	Gürsoy G, DEMİRBAŞ B (2019). HİPOFİZ ADENOMLARINDA RADYOTERAPİ. , 174 - 180.
Chicago	Gürsoy Gül,DEMİRBAŞ Berrin ÇARMIKLI HİPOFİZ ADENOMLARINDA RADYOTERAPİ. (2019): 174 - 180.
MLA	Gürsoy Gül,DEMİRBAŞ Berrin ÇARMIKLI HİPOFİZ ADENOMLARINDA RADYOTERAPİ. , 2019, ss.174 - 180.
AMA	Gürsoy G,DEMİRBAŞ B HİPOFİZ ADENOMLARINDA RADYOTERAPİ. . 2019; 174 - 180.
Vancouver	Gürsoy G,DEMİRBAŞ B HİPOFİZ ADENOMLARINDA RADYOTERAPİ. . 2019; 174 - 180.
IEEE	Gürsoy G,DEMİRBAŞ B "HİPOFİZ ADENOMLARINDA RADYOTERAPİ." , ss.174 - 180, 2019.
ISNAD	Gürsoy, Gül - DEMİRBAŞ, Berrin ÇARMIKLI. "HİPOFİZ ADENOMLARINDA RADYOTERAPİ". (2019), 174-180.

APA	Gürsoy G, DEMİRBAŞ B (2019). HİPOFİZ ADENOMLARINDA RADYOTERAPİ. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, 52(2), 174 - 180.
Chicago	Gürsoy Gül,DEMİRBAŞ Berrin ÇARMIKLI HİPOFİZ ADENOMLARINDA RADYOTERAPİ. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi 52, no.2 (2019): 174 - 180.
MLA	Gürsoy Gül,DEMİRBAŞ Berrin ÇARMIKLI HİPOFİZ ADENOMLARINDA RADYOTERAPİ. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, vol.52, no.2, 2019, ss.174 - 180.
AMA	Gürsoy G,DEMİRBAŞ B HİPOFİZ ADENOMLARINDA RADYOTERAPİ. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2019; 52(2): 174 - 180.
Vancouver	Gürsoy G,DEMİRBAŞ B HİPOFİZ ADENOMLARINDA RADYOTERAPİ. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2019; 52(2): 174 - 180.
IEEE	Gürsoy G,DEMİRBAŞ B "HİPOFİZ ADENOMLARINDA RADYOTERAPİ." Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, 52, ss.174 - 180, 2019.
ISNAD	Gürsoy, Gül - DEMİRBAŞ, Berrin ÇARMIKLI. "HİPOFİZ ADENOMLARINDA RADYOTERAPİ". Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi 52/2 (2019), 174-180.